# Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment

> **NCT01934465** · — · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 300 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01934465
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934465, "Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01934465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*